GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cyclo Therapeutics Inc (NAS:CYTH) » Definitions » Shiller PE Ratio

Cyclo Therapeutics (Cyclo Therapeutics) Shiller PE Ratio : (As of May. 23, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Cyclo Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cyclo Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Cyclo Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclo Therapeutics Shiller PE Ratio Chart

Cyclo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cyclo Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cyclo Therapeutics's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Cyclo Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyclo Therapeutics's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cyclo Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cyclo Therapeutics's Shiller PE Ratio falls into.



Cyclo Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Cyclo Therapeutics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Cyclo Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.15/131.7762*131.7762
=-0.150

Current CPI (Mar. 2024) = 131.7762.

Cyclo Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.291 100.560 -0.381
201409 -0.410 100.428 -0.538
201412 -0.583 99.070 -0.775
201503 -1.000 99.621 -1.323
201506 -1.000 100.684 -1.309
201509 -1.000 100.392 -1.313
201512 -2.000 99.792 -2.641
201603 -1.000 100.470 -1.312
201606 -2.000 101.688 -2.592
201609 -2.000 101.861 -2.587
201612 -2.000 101.863 -2.587
201703 -1.000 102.862 -1.281
201706 -1.000 103.349 -1.275
201709 -1.000 104.136 -1.265
201712 -2.000 104.011 -2.534
201803 -1.000 105.290 -1.252
201806 -2.000 106.317 -2.479
201809 -1.000 106.507 -1.237
201812 -1.000 105.998 -1.243
201903 -2.000 107.251 -2.457
201906 -1.000 108.070 -1.219
201909 -1.000 108.329 -1.216
201912 -2.168 108.420 -2.635
202003 -2.167 108.902 -2.622
202006 -1.548 108.767 -1.875
202009 -0.845 109.815 -1.014
202012 -0.562 109.897 -0.674
202103 -0.760 111.754 -0.896
202106 -0.560 114.631 -0.644
202109 -0.600 115.734 -0.683
202112 -0.340 117.630 -0.381
202203 -0.330 121.301 -0.358
202206 -0.410 125.017 -0.432
202209 -0.500 125.227 -0.526
202212 -0.590 125.222 -0.621
202303 -0.460 127.348 -0.476
202306 -0.330 128.729 -0.338
202309 -0.290 129.860 -0.294
202312 -0.230 129.419 -0.234
202403 -0.150 131.776 -0.150

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cyclo Therapeutics  (NAS:CYTH) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Cyclo Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Cyclo Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyclo Therapeutics (Cyclo Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
6714 North West 16th Street, Suite B, Gainesville, FL, USA, 32653
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company develops cyclodextrin-based products for the treatment of disease. Its drug candidate, Trappsol Cyclo, treats Niemann-Pick Type C disease (NPC). Its other products include Trappsol HPB, Trappsol Fine Chemical, and Aquaplex.
Executives
Vivien Wong director 6C CHATEAUX CIRCLE, SCARSDALE NY 10583
Rafael Holdings, Inc. 10 percent owner 520 BROAD STREET, NEWARK NJ 07120
William Conkling director C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Jeffrey Tate director, officer: Chief Executive Officer C/O CTD HOLDINGS, INC., 27317 NW 78TH AVENUE, HIGH SPRINGS FL 32643
Francis Patrick Ostronic director 932 HUNGERFORD DRIVE, SUITE 28A, ROCKVILLE MD 20850
Markus Sieger director BEUTSTWEG 12, CH-8032, ZURICH V8 000000000
N Scott Fine director 600 3RD AVE, NEW YORK NY 10016
Sharon Hemond Hrynkow officer: SVP for Medical Affairs 4816 KING SOLOMON DRIVE, ANNADALE VA 22003
Lise Lund Kjems officer: Chief Medical Officer 91 ROLLINGWOOD LN., CONCORD MA 01742
Joshua M Fine officer: Chief Financial Officer 21 HEMMELSKAMP ROAD, WILTON CT 06897
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Michael Eric Lisjak officer: Chief Regulatory Officer 12 ROOSEVELT AVENUE, OLD GREENWICH CT 06870
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
L.p. Novit, 10 percent owner 966 HUNGERFORD DRIVE, ROCKVILLE MD 20850